2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study | Cardiovascular Diabetology | Full Text
MedShr - Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus: http://ow.ly/gDgm30llOjs Add comments to trending Cardiology discussions on MedShr! Antihyperglycemic Diabetologia Association of Clinical Diabetologists ...
New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin | tctmd.com
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease
Abstract 9946: Dapagliflozin versus Empagliflozin for Improving Outcomes of Type 2 Diabetes Mellitus Patients with Heart Failure and Reduced Ejection Fraction | Circulation
PDF) Longitudinal HbA1c trajectory modelling reveals the association of HbA1c and risk of hospitalization for heart failure for patients with type 2 diabetes mellitus
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
JPM | Free Full-Text | Diabetes Mellitus and Heart Failure
Body Weight Related to Beneficial Effects of SGLT-2 Inhibitors in Patients with Type 2 Diabetes in New Analysis
![PDF] Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d55aed26c00771408b8f67f2e1d8c8900056668f/6-Table3-1.png "PDF] Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes | Semantic Scholar")
PDF] Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes | Semantic Scholar
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
Diabetes drugs now 'pillars of care' for heart failure
Reducing Risk of Major Adverse Cardiovascular Events: Role of SGLT2 Inhibitors, GLP-1 Agonists - Endocrinology Advisor
Diabetes Canada | Clinical Practice Guidelines - Chapter 13: Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Managing Type 2 Diabetes And Cardiovascular Disease - HbA1c
Journal of Diabetes Investigation: Vol 13, No 7
Relationship between hypoglycaemia, cardiovascular (CV) outcomes and all-cause mortality (ACM) in type 2 diabetes (T2D) in the CARMELINA trial - Media Centre | EASD
The effects of antidiabetic agents on heart failure | SpringerLink
The effect of DPP-4is on HHF in type 2 diabetic patients with and... | Download Scientific Diagram
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus - ScienceDirect
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database,Journal of Diabetes Investigation - X-MOL
A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction - Kashiwagi - 2019 - Journal of Diabetes Investigation - Wiley Online Library
Häufiger Herzinsuffizienz- bedingte Hospitalisierungen?
